Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Sahajanand Medical Technologies Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹327 - ₹344
Per ShareLot Size
43 Shares
Minimum Investment
₹14,061
Issue Size
₹0 Cr
Face Value
₹1
Per ShareIPO Type
Book Building
Retail Quota
0%
QIB Quota
0%
NII Quota
0%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Issue Type
Book Building
ISIN
INE356Y01018
We are engaged in the development of Class III1 and Class C/D2 medical devices, with an emphasis on Vascular Intervention ("VI") and Structural Heart ("SH"). Our portfolio of (i) VI products includes coronary intervention products such as coronary stents and coronary balloons, (ii) SH products includes Trans-Catheter Aortic Valves and Occluders, and (iii) other products including our own brand of renal stents, peripheral drug coated balloons and other trading products.
The global vascular devices market can be segmented into Vascular Interventional Devices (comprising of cardiovascular and peripheral interventions) and Structural Heart Devices. The global vascular devices market has witnessed consistent growth over the past decade, driven by increasing prevalence of cardiovascular disease and peripheral vascular disease, technological advancements, and rising healthcare expenditure. In 2024, the market is valued at approximately USD 24.3 billion, with a 6.2% CAGR over the past five years.
Our Company was initially formed as a partnership firm named `Sahajanand Vascular Technoventions' pursuant to a partnership deed dated October 25, 1999. Subsequently, pursuant to a partnership deed dated September 30, 2001, the partnership firm was re-constituted, and the name of the partnership firm was changed to `Sahajanand Medical Technologies'. Subsequently, the partnership firm was converted into a joint stock company and was registered as a private limited company named `Sahajanand Medical Technologies Private Limited' pursuant to a certificate of incorporation dated October 18, 2001, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli, in accordance with provisions of the Companies Act, 1956. Subsequently, our Company was converted into a public limited company, pursuant to a special resolution of our Shareholders dated April 27, 2021, and the name of our Company was changed to `Sahajanand Medical Technologies Limited', and a fresh certificate of incorporation dated May 7, 2021 was issued to our Company by the Registrar of Companies, Gujarat at Ahmedabad ("RoC").
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offering of up to 27,644,231 equity shares of face value of Re. 1/- each ("Equity Shares") of Sahajanand Medical Technologies Limited (the "Company" or the "Issuer") for cash at a price of Rs. [*] per equity share (Including a share Premium of Rs. [*] per equity share) (the "Offer Price") aggregating up to Rs. [*] crores through an offer for sale (the "Offer"), consisting of up to 2,700,000 equity shares of face value of Re.1/- each aggregating up to Rs.[*] crores by Shree Hari Trust, up to 2,700,000 equity shares of face value of Re.1/- each aggregating up to Rs.[*] crores by Dhirajkumar Savjibhai Casoya, up to 12,958,126 equity shares of face value of Re.1/- each aggregating up to Rs.[*] crores by Samara Capital Markets Holding Limited, up to 2,615,750 equity shares of face value of Re.1/- each aggregating up to Rs.[*] crores by Kotak Pre-IPO Opportunities Fund, up to 6,670,355 equity shares of face value of Re.1/- each aggregating up to Rs.[*] crores by Nhpea Sparkle Holding B.V. (Collectively, the "Selling Shareholders" and such equity shares, the "Offered Shares"). The offer includes a reservation of up to [*] equity shares of face value of Re.1/- each (Constituting [*]% of the post issue paid up equity share capital of the Company) aggregating up to Rs.[*] crores for subscription by eligible employees (the "Employee Reservation Portion"). The company, in consultation with the book running lead managers, may offer a discount of up to [*] % (Equivalent of Rs. [*] per Equity Share) to the offer price to eligible employees bidding under the employee reservation portion ("Employee Discount"). The offer less the employee reservation portion is hereinafter referred to as the "Net Offer". The offer and the net offer will constitute [*]% and [*]% of the post-offer paid-up equity share capital, respectively. The face value of the equity shares is Re. 1/- each. The offer price is [*] times the face value of the equity shares. The price band and the minimum bid lot size will be decided by the company.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
The Company manufactures and supplies its products domestically and to certain key markets in Europe based on orders received directly from end-customers, i.e., hospitals and doctors.
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY23 to FY25.